The Neurological Biomarkers for Alzheimer's Disease market
generated a revenue of $2,636.7 million in 2017 and is expected to reach
$6,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. In
contrast, the market for neurological biomarkers will reach $2,122.5 million by
2025, and is expected to reach $2,457.4 million by 2025, registering a CAGR of
8.0%.
Explore Moe Insights@ https://www.alliedmarketresearch.com/request-sample/3555
A strong increase in neurological biomarkers is expected to
increase the incidence of Alzheimer's and Parkinson's diseases. In addition,
there has been an increase in the adoption of neurological biomarkers in drug
development and validation to improve the accuracy of clinical trials.
On the basis of region, the neurological biomarkers market for
Alzheimer's and Parkinson's diseases is studied in US, EU5, Rest of Europe,
China, Asia-Pacific and Rest of World (ROW). The US dominated the Alzheimer's
and Parkinson's market in 2017 and is expected to continue this trend
throughout the forecast period.
Key Benefits:
- Asia-Pacific is expected to register the
highest growth rate from 2018 to 2025 in the neurological biomarkers
market for Alzheimers.
- The U.S. accounted for maximum revenue in 2017
in the market for both Alzheimers and Parkinsons, and is anticipated to
maintain this trend throughout the forecast period.
- EU5 region generated second highest revenue in
2017 in the market for both Alzheimers & Parkinsons, and is expected
to continue this trend throughout the forecast period.
- China is estimated to exhibit the highest CAGR
of 10.1% from 2018 to 2025 in the neurological biomarkers market for
Parkinsons disease.
Top Leading Company:
·
Abbott Laboratories,
·
Myriad RBM,
·
Proteome Sciences,
·
Thermo Fisher Scientific,
·
Athena Diagnostics,
·
Immunarray Pvt. Ltd.,
·
Quanterix Corporation,
·
Diagenic ASA,
·
Psynova Neurotech,
·
Bio-Rad Laboratories.
0 Comments